Generation Bio Co. Stock Price, News & Analysis

Compass Pathways (Nasdaq: CMPS) appointed Dr. Jeffrey Jonas to its Board of Directors effective immediately and announced the retirement of Thomas Lönngren at the end of December after more than six years of service.

Dr. Jonas brings more than 30 years of pharmaceutical R&D and neuroscience leadership, executive experience at Sage Therapeutics and Shire, current board roles at Generation Bio (GBIO) and Noema Pharma, and an extensive publication record; the company cited his expertise as supportive for potential commercialization of COMP360.

Generation Bio (Nasdaq: GBIO) announced a leadership transition effective October 31, 2025. Geoff McDonough, MD will step down as Chief Executive Officer and President and become Chair of the Board. The Board appointed Yalonda Howze, JD, currently Chief Legal Officer since April 2023, as Interim CEO and President. Jason Rhodes will step down as Board Chair and remain a director. The company described the change as a transition and expressed confidence in Howze’s interim leadership.

Generation Bio (NASDAQ: GBIO) announced significant developments in its cell-targeted lipid nanoparticle (ctLNP) delivery system and reported Q2 2025 financial results. The company achieved a breakthrough with first-ever siRNA delivery to T cells in non-human primates, demonstrating selective delivery and potent knockdown of target proteins.

Despite these advances, GBIO is implementing a strategic restructuring, including a 90% workforce reduction between August-October 2025. The company has retained TD Cowen to explore strategic alternatives, including potential merger, acquisition, or asset sale. Financial highlights include a cash position of $141.4M as of June 30, 2025, and a Q2 net loss of $20.9M. Additionally, GBIO settled a lease litigation for $31M, extinguishing a $58M lease liability.

Generation Bio (Nasdaq: GBIO) has announced a 1-for-10 reverse stock split effective July 21, 2025, at 5:00 pm Eastern Time. The split will reduce outstanding shares from approximately 67.3 million to 6.7 million. Trading on a split-adjusted basis will begin July 22, 2025, under the same symbol "GBIO" but with a new CUSIP number (37148K 209).

The reverse split, approved by stockholders on June 4, 2025, aims to increase the per-share market price to regain compliance with Nasdaq's minimum bid price requirement. The split will not affect the number of authorized shares or par value. Proportionate adjustments will be made to equity incentive plans, and stockholders will receive cash payments for any fractional shares.

Generation Bio (Nasdaq:GBIO), a biotechnology company focused on T cell-driven autoimmune diseases, has granted equity awards to a new employee under its 2025 Inducement Stock Incentive Plan. The grant includes non-statutory stock options for 128,600 shares at an exercise price of $0.32 per share.

The options have a 10-year term with a four-year vesting schedule: 25% vesting after one year and 6.25% vesting quarterly thereafter, contingent on continued employment.

Generation Bio (Nasdaq: GBIO), a biotechnology company focused on developing treatments for T cell-driven autoimmune diseases, has announced that its President and CEO, Geoff McDonough, M.D., will deliver a presentation at the upcoming Jefferies Global Healthcare Conference. The presentation is scheduled for Wednesday, June 4th, 2025, at 8:10 a.m. ET.

Interested parties can access a live webcast of the presentation through the investor section of Generation Bio's website at investors.generationbio.com. A replay of the presentation will remain available on the website for 30 days after the event.

Generation Bio (GBIO) reported its Q1 2025 financial results and business updates. The company is developing first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA. The company plans to announce its lead target and portfolio strategy in mid-2025.

Financial highlights include a cash position of $157.6 million as of March 31, 2025, expected to fund operations into 2H 2027. Q1 2025 results showed R&D expenses of $15.4 million (up from $14.3M in Q1 2024), G&A expenses of $8.8 million (down from $10.4M), and a net loss of $14.8 million ($0.22 per share), significantly improved from a $74.5 million loss ($1.12 per share) in Q1 2024.

Generation Bio (Nasdaq: GBIO), a biotechnology company focused on T cell-driven autoimmune diseases, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.

The company's President and CEO, Geoff McDonough, M.D., will engage in a fireside chat scheduled for Wednesday, April 9th at 12:45 p.m. ET. Investors and interested parties can access the live webcast through the investor section at investors.generationbio.com, where a replay will remain available for 30 days after the event.

Generation Bio (GBIO) reported its Q4 and full year 2024 financial results, highlighting its focus on developing siRNA therapeutics for T cell-driven autoimmune diseases. The company's T cell-selective lipid nanoparticle (LNP) technology achieved approximately 98% knockdown of B2M protein in human T cells in both in vitro and mouse studies.

Key financial metrics include a cash position of $185.2 million as of December 31, 2024, expected to fund operations into 2H 2027. R&D expenses were $15.5 million for Q4 and $61.3 million for FY2024. The company reported a net loss of $21.4 million ($0.32 per share) for Q4 and $131.7 million ($1.98 per share) for FY2024.

Generation Bio plans to announce its lead target and indication in mid-2025, with an IND application scheduled for second half of 2026.